^
    Back
    Association details:
    Biomarker:EPHA3 positive
    Cancer:Glioblastoma
    Drug:ifabotuzumab (KB004) (EPH receptor inhibitor, EphA3 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    AACR 2021
    Title:

    CT101 - Phase I safety and bioimaging trial of ifabotuzumab in patients with glioblastoma.

    Published date:
    03/10/2021
    Excerpt:
    ...Zr- ifabotuzumab, the frequency of EphA3 positive GBM...Ifabotuzumab demonstrates highly sensitive, specific and reproducible targeting of the tumor and tumor microenvironment in all patients in this study…